Jeffrey Gross
Neurology · Fairfield, CTNPI 1770549180
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $38,639 of the $52,170 with a category attached, or 74.1%. 34 manufacturers reported payments, led by Sanofi at 29.3% of the total. Reporting peaked in 2019 at $35,847 and has fallen 99.2% since, to $272 in 2022.
Across 254 payments — averaging $205.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$15K
- AstraZeneca$11K
- Genentech USA, Inc.$11K
- EMD Serono, Inc.$6K
- Novartis$6K
- Biogen$485
- plus $2K from 28 others
Across 81 payments — averaging $5290.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$169K
- Novartis$137K
- Adamas Pharmaceuticals, Inc.$36K
- Genentech, Inc.$30K
- Roche Products Limited$18K
- Sanofi$16K
- plus $21K from 4 others
What the payments were for
- Consulting fees$4,5199%
- Speaking & faculty fees$38,63974%
- Travel & lodging$2,7335%
- Food & beverage$6,16912%
- Education$1110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 38 | $15,301 |
| AstraZeneca | 20 | $11,295 |
| Genentech USA, Inc. | 28 | $11,155 |
| EMD Serono, Inc. | 21 | $6,227 |
| Novartis | 35 | $6,152 |
| Biogen | 24 | $485 |
| Teva Pharmaceuticals USA, Inc. | 16 | $196 |
| AbbVie(2 entities) | 4 | $154 |
| UCB, Inc. | 11 | $152 |
| Adamas Pharmaceuticals, Inc. | 5 | $98 |
| Eisai Inc. | 4 | $83 |
| Acorda Therapeutics, Inc | 5 | $82 |
| Acadia Pharmaceuticals Inc | 5 | $81 |
| Akcea Therapeutics, Inc. | 3 | $72 |
| CSL Behring | 4 | $72 |
| Amgen | 3 | $56 |
| Lundbeck LLC | 3 | $54 |
| Genentech, Inc. | 1 | $50 |
| Avanir Pharmaceuticals, Inc. | 4 | $49 |
| Amneal Pharmaceuticals LLC | 3 | $46 |
| Boston Scientific | 1 | $45 |
| Alnylam Pharmaceuticals Inc. | 2 | $43 |
| Assertio Therapeutics, Inc. | 2 | $35 |
| MDD US Operations, LLC | 2 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| GE HealthCare | 1 | $19 |
| Lilly USA, LLC | 1 | $18 |
| Promius Pharma LLC | 1 | $18 |
| Vertical Pharmaceuticals, LLC | 1 | $18 |
| Supernus Pharmaceuticals, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Merz North America, Inc. | 1 | $13 |
| Tanabe Pharma America, Inc. | 1 | $12 |
| Grifols USA, LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$52,170 in reported general payments places this provider in the 85th percentile of 280 neurology providers in Connecticut.
Other neurology in Fairfield
- Peter McAllisterFairfield$2.3M
- Peter GottschalkFairfield$318K
- Nicholas BlondinFairfield$93K
- Srinath KadimiFairfield$32K
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.